Loading data for UPB — first visit, this takes a few seconds.

Alert

Upstream Bio Inc. (UPB)

NasdaqGS: UPB · Real-Time Price · USD

7.51

+0.66 (9.64%)

At close: Aug 19, 2026, 8:00 PM

7.66

+1.93%

After-hours: 7:30 PM

9.64% (1D)

No data available

Bid	5.41
Market Cap	411.6M
Revenue (ttm)	3.16M
Net Income (ttm)	-156.5M
Beta	n/a
EPS (ttm)	-3.16
PE Ratio (ttm)	n/a
Forward PE	-2.56
P/B (ttm)	1.35
P/S (ttm)	130.34
Earnings Date	Nov 4, 2026

Ask	8.94
Volume	558,053
Avg. Volume (20D)	607,041
Open	7.04
Previous Close	6.85
Day's Range	6.93 - 7.52
52-Week Range	5.85 - 33.68
Analyst	Buy
Price Target	30.5 (306.13%)
Dividends	n/a
Ex-Dividend Date	n/a

About UPB

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headqu...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 11, 2024

Employees 75

Stock Exchange NasdaqGS

Ticker Symbol UPB

Website https://upstreambio.com

Full Company Profile

Financial Performance

In 2025, Upstream Bio's revenue was 2.85M, an increase of 20.42% compared to the previous year's 2.37M. Earnings were -143.44M, an increase of 128.39%.

Financial Statements

Analyst Forecast

According to 8 analyst ratings, the average rating for UPB stock is "Buy". The 12-month stock price forecast is 30.5, which is upside of 306.13% from the latest price.

Stock Forecasts

Earnings Surprise

Upstream Bio has released their quarterly earnings on Aug 11, 2026:

Revenue of $1.03M misses estimates by $0, with 82.69% YoY growth.

EPS of -0.73 exceeds estimates by 0.03, with 1.35% YoY growth.

Next Earnings Release

Upstream Bio Inc. is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · Zacks

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 month ago · Zacks

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · Insider Monkey

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Upstream Bio, Inc. (NASDAQ:UPB) is one of the most promising stocks on our list. TheFly reported ...

1 month ago · Insider Monkey

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

Upstream Bio, Inc. (NASDAQ:UPB) is among the best low priced stocks to get rich in 2026. On June 12, JPMorgan significantly trimmed the price target on Upstream Bio, Inc. (NASDAQ:UPB) to $8 from $35, ...

3 months ago · Zacks

Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Page 1 of 2

Upstream Bio Inc. (UPB)